Log in

RDG Read-Gene SA GPW · Poland

Read-Gene SA (RDG) news

Read-Gene SA is a public biotech or pharmaceutical company listed on GPW under the ticker RDG, recorded under Poland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Read-Gene SA news

We have not published a story on Read-Gene SA yet. When there is news, it will appear here.

Questions about Read-Gene SA

What is the ticker symbol of Read-Gene SA?

Read-Gene SA trades under the ticker RDG on GPW.

Where is Read-Gene SA listed?

Read-Gene SA is listed on GPW.

Which country or territory is Read-Gene SA listed under?

Our directory records Read-Gene SA under Poland.

What does Read-Gene SA do?

Our directory classifies Read-Gene SA as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Read-Gene SA?

The ISIN recorded for Read-Gene SA is PLRADGN00014.

Does aibio.space cover Read-Gene SA?

aibio.space lists Read-Gene SA among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Read-Gene SA?

Companies in our directory listed in the same country and business area as Read-Gene SA: Selvita SA, genXone SA, Mabion SA, QNA Technology SA, Adiuvo Investment, MultiQure.

Investor discussion: Read-Gene SA

Members talk about Read-Gene SA (RDG). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open GPW:RDG on TradingView.

Listing details

Read-Gene SA is a public biotech or pharmaceutical company listed on GPW under the ticker RDG, recorded under Poland. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Read-Gene SA
Ticker
RDG
Listing
GPW
Country or territory
Poland
Business scope
Biotechnology
ISIN
PLRADGN00014
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.